• Processa Pharmaceuticals: Director, President of Research & Development David Young bought 2,531 common shares at $1.93.
• Directly held common stock rose to 21,729 shares.
• Also reported indirect holdings of 2,683 shares through a revocable trust, family entities, and CorLyst.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Processa Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000897069-26-001476), on July 01, 2026, and is solely responsible for the information contained therein.